At a glance
ClinicalIndex Comparison Record- ✓Non-squamous NSCLC confirmed histologically or cytologically
- ✓Stage IIIB, IIIC, or IV metastatic NSCLC not amenable to curative surgery or definitive chemoradiation
- ✓Absence of sensitizing EGFR mutations, ALK and ROS1 rearrangements, and no documented local test result for other genomic alterations with approved targeted first-line therapies
- ✓Tumor PD-L1 expression TC ≥50%
- ✕Prior systemic therapy for advanced/metastatic NSCLC
- ✕Squamous cell, predominantly squamous cell, mixed small cell, or sarcomatoid variant histology
- ✕History of another primary malignancy within 3 years
- ✕Active or prior documented autoimmune or inflammatory disorders (with exceptions)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
In the news
1 article- Samsung Bioepis宣布其Keytruda (Pembrolizumab)候选生物类似药SB27的积极1期和3期初步研究数据Business Wire Pharma·2026-06-29press release
Matched to this trial by ClinicalIndexfrom reputable biotech & medical press.
A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)
In Brief
A Phase 3 clinical trial evaluating Datopotamab Deruxtecan, Rilvegostomig, and 1 other intervention for Non-Small Cell Lung Cancer. Currently recruiting, targeting 675 participants across 283 sites in 21 countries.
Signals
Detailed Summary
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.
Study Details
Timeline
Arms & Interventions
Participants in the Datopotamab Deruxtecan (Dato-DXd) in combination with Rilvegostomig group will receive Dato-DXd plus rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
Participants in the rilvegostomig monotherapy group will receive rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
Participants in the pembrolizumab group will receive pembrolizumab as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
Interventions
Datopotamab Deruxtecan IV (intravenous)
Rilvegostomig IV (intravenous)
Pembrolizumab IV (intravenous)